Ahuja Nita 4

What Happened
Nita Ahuja, a director of Abbott Laboratories (ABT), was reported to have been granted/credited 102 stock-equivalent shares (derivative acquisition) on March 31, 2026. The filing shows an acquisition price basis of $102.67 per share, for a notional total of about $10,472. This was an award/credit of director compensation (not an open-market purchase or sale).

Key Details

• Transaction date: 2026-03-31 (reported on Form 4 filed 2026-04-02). Filing appears timely.
• Transaction type/code: A — Grant/award or other acquisition (derivative).
• Amount and price: 102 shares at $102.67 each; notional value ≈ $10,472.
• Shares owned after transaction: Not specified in the provided filing.
• Footnote: Director fees were credited to a stock-equivalent unit account and are generally paid in cash at age 65 or upon retirement; the stock-equivalent units earn the same return as if fees were invested in Abbott shares.

Context
This is a routine director compensation credit (stock-equivalent units) rather than a cash purchase or sale of company stock. Such awards typically reflect compensation practices and do not by themselves indicate the director is buying or selling shares in the open market.